Lexicon Net Receivables vs Cash And Short Term Investments Analysis

LXRX Stock

USD 1.77 0.07 3.80%

Lexicon Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Lexicon Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lexicon Pharmaceuticals is a good investment. Please check the relationship between Lexicon Pharmaceuticals Net Receivables and its Cash And Short Term Investments accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Net Receivables vs Cash And Short Term Investments

Net Receivables vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lexicon Pharmaceuticals Net Receivables account and Cash And Short Term Investments. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Lexicon Pharmaceuticals' Net Receivables and Cash And Short Term Investments is 0.13. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Lexicon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Lexicon Pharmaceuticals' Net Receivables and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Lexicon Pharmaceuticals are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Net Receivables i.e., Lexicon Pharmaceuticals' Net Receivables and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.13

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Lexicon Pharmaceuticals balance sheet. This account contains Lexicon Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Lexicon Pharmaceuticals fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from Lexicon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lexicon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.At this time, Lexicon Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 145.7 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (2.59) in 2024.

	2023	2024 (projected)
Extraordinary Items	3.6M	3.2M
Reconciled Depreciation	510K	484.5K

Extraordinary Items Reconciled Depreciation

Lexicon Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Assets
Total Assets		0.41	0.36	0.68	0.39	0.36	0.51	-0.57	-0.11	0.47	0.84	0.74	0.13	0.98	0.18	-0.05	0.88	0.72	0.53	0.43	0.78	0.3	0.98	0.33	0.53	-0.39
Short Long Term Debt Total	0.41		0.57	0.46	-0.21	-0.12	0.25	0.37	-0.35	0.54	0.17	0.19	-0.18	0.38	0.57	0.15	0.51	0.89	0.1	-0.11	0.83	-0.17	0.44	0.07	0.24	-0.22
Other Current Liab	0.36	0.57		0.57	-0.24	-0.19	0.57	0.22	-0.23	0.39	0.08	-0.04	-0.15	0.38	0.72	0.2	0.64	0.53	0.03	-0.18	0.6	-0.22	0.45	-0.14	0.09	-0.06
Total Current Liabilities	0.68	0.46	0.57		0.31	-0.02	0.82	-0.37	-0.18	0.86	0.65	0.3	-0.13	0.74	0.16	0.05	0.8	0.58	0.12	0.35	0.8	-0.09	0.73	0.28	0.25	-0.29
Total Stockholder Equity	0.39	-0.21	-0.24	0.31		0.2	0.12	-0.55	0.31	0.18	0.48	0.24	-0.2	0.44	-0.35	-0.18	0.35	-0.02	0.38	0.78	0.1	0.12	0.4	0.45	-0.12	-0.25
Property Plant And Equipment Net	0.36	-0.12	-0.19	-0.02	0.2		-0.22	-0.39	0.41	0.02	0.35	0.77	-0.17	0.22	-0.03	-0.46	0.2	0.19	-0.15	0.14	0.13	0.98	0.19	0.14	0.13	-0.48
Current Deferred Revenue	0.51	0.25	0.57	0.82	0.12	-0.22		-0.29	-0.43	0.59	0.46	0.03	0.13	0.63	0.09	0.38	0.64	0.36	0.0	0.28	0.57	-0.22	0.61	-0.08	0.35	0.11
Net Debt	-0.57	0.37	0.22	-0.37	-0.55	-0.39	-0.29		-0.33	-0.17	-0.86	-0.49	-0.23	-0.6	0.48	0.43	-0.37	-0.02	-0.39	-0.38	-0.15	-0.35	-0.53	-0.34	-0.16	0.42
Retained Earnings	-0.11	-0.35	-0.23	-0.18	0.31	0.41	-0.43	-0.33		-0.26	0.14	0.0	-0.13	-0.12	-0.06	-0.89	-0.16	-0.22	-0.05	-0.22	-0.23	0.33	-0.13	0.34	-0.75	-0.6
Accounts Payable	0.47	0.54	0.39	0.86	0.18	0.02	0.59	-0.17	-0.26		0.49	0.31	-0.24	0.49	0.04	0.09	0.65	0.56	-0.01	0.29	0.73	-0.02	0.47	0.24	0.25	-0.18
Cash	0.84	0.17	0.08	0.65	0.48	0.35	0.46	-0.86	0.14	0.49		0.63	0.13	0.86	-0.21	-0.35	0.69	0.52	0.48	0.37	0.62	0.27	0.82	0.39	0.31	-0.55
Non Current Assets Total	0.74	0.19	-0.04	0.3	0.24	0.77	0.03	-0.49	0.0	0.31	0.63		-0.08	0.6	-0.06	-0.17	0.53	0.52	0.27	0.38	0.5	0.74	0.58	0.19	0.56	-0.39
Non Currrent Assets Other	0.13	-0.18	-0.15	-0.13	-0.2	-0.17	0.13	-0.23	-0.13	-0.24	0.13	-0.08		0.2	-0.1	0.1	-0.03	-0.11	0.21	-0.24	-0.13	-0.06	0.18	0.17	0.21	0.25
Cash And Short Term Investments	0.98	0.38	0.38	0.74	0.44	0.22	0.63	-0.6	-0.12	0.49	0.86	0.6	0.2		0.13	-0.01	0.89	0.67	0.54	0.45	0.77	0.16	0.99	0.33	0.47	-0.34
Net Receivables	0.18	0.57	0.72	0.16	-0.35	-0.03	0.09	0.48	-0.06	0.04	-0.21	-0.06	-0.1	0.13		-0.01	0.3	0.41	-0.06	-0.37	0.36	-0.08	0.23	0.13	0.04	-0.23
Common Stock Shares Outstanding	-0.05	0.15	0.2	0.05	-0.18	-0.46	0.38	0.43	-0.89	0.09	-0.35	-0.17	0.1	-0.01	-0.01		0.07	0.02	-0.03	0.3	0.03	-0.36	-0.01	-0.48	0.49	0.84
Short Term Investments	0.88	0.51	0.64	0.8	0.35	0.2	0.64	-0.37	-0.16	0.65	0.69	0.53	-0.03	0.89	0.3	0.07		0.71	0.41	0.39	0.82	0.16	0.9	0.18	0.38	-0.27
Non Current Liabilities Total	0.72	0.89	0.53	0.58	-0.02	0.19	0.36	-0.02	-0.22	0.56	0.52	0.52	-0.11	0.67	0.41	0.02	0.71		0.22	0.05	0.95	0.12	0.7	0.1	0.35	-0.37
Other Current Assets	0.53	0.1	0.03	0.12	0.38	-0.15	0.0	-0.39	-0.05	-0.01	0.48	0.27	0.21	0.54	-0.06	-0.03	0.41	0.22		0.41	0.21	-0.21	0.56	0.31	0.3	-0.16
Other Stockholder Equity	0.43	-0.11	-0.18	0.35	0.78	0.14	0.28	-0.38	-0.22	0.29	0.37	0.38	-0.24	0.45	-0.37	0.3	0.39	0.05	0.41		0.17	0.11	0.4	0.16	0.35	0.06
Total Liab	0.78	0.83	0.6	0.8	0.1	0.13	0.57	-0.15	-0.23	0.73	0.62	0.5	-0.13	0.77	0.36	0.03	0.82	0.95	0.21	0.17		0.06	0.79	0.17	0.35	-0.38
Property Plant And Equipment Gross	0.3	-0.17	-0.22	-0.09	0.12	0.98	-0.22	-0.35	0.33	-0.02	0.27	0.74	-0.06	0.16	-0.08	-0.36	0.16	0.12	-0.21	0.11	0.06		0.13	0.05	0.18	-0.33
Total Current Assets	0.98	0.44	0.45	0.73	0.4	0.19	0.61	-0.53	-0.13	0.47	0.82	0.58	0.18	0.99	0.23	-0.01	0.9	0.7	0.56	0.4	0.79	0.13		0.34	0.47	-0.35
Short Term Debt	0.33	0.07	-0.14	0.28	0.45	0.14	-0.08	-0.34	0.34	0.24	0.39	0.19	0.17	0.33	0.13	-0.48	0.18	0.1	0.31	0.16	0.17	0.05	0.34		-0.04	-0.52
Common Stock	0.53	0.24	0.09	0.25	-0.12	0.13	0.35	-0.16	-0.75	0.25	0.31	0.56	0.21	0.47	0.04	0.49	0.38	0.35	0.3	0.35	0.35	0.18	0.47	-0.04		0.16
Other Assets	-0.39	-0.22	-0.06	-0.29	-0.25	-0.48	0.11	0.42	-0.6	-0.18	-0.55	-0.39	0.25	-0.34	-0.23	0.84	-0.27	-0.37	-0.16	0.06	-0.38	-0.33	-0.35	-0.52	0.16

Click cells to compare fundamentals

Lexicon Pharmaceuticals Account Relationship Matchups

Lexicon Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	417.7M	203.8M	136.9M	194.3M	229.4M	326.8M
Short Long Term Debt Total	246.3M	12.8M	2.3M	55.3M	106.1M	75.1M
Other Current Liab	42.2M	976K	11.9M	11.5M	15.9M	11.6M
Total Current Liabilities	65.3M	46.8M	22.1M	23.2M	31.5M	48.4M
Total Stockholder Equity	(1.3B)	156.4M	(1.5B)	(1.6B)	93.1M	97.8M
Property Plant And Equipment Net	14.0M	295K	1.2M	2.1M	7.5M	7.1M
Net Debt	210.2M	(113.5M)	(61.8M)	8.9M	83.6M	87.8M
Retained Earnings	(1.3B)	(1.4B)	(1.5B)	(1.6B)	(1.8B)	(1.7B)
Accounts Payable	12.2M	5.5M	9.2M	10.4M	14.4M	13.3M
Cash	36.1M	126.3M	64.1M	46.3M	22.5M	21.3M
Non Current Assets Total	80.0M	46.1M	48.0M	53.4M	52.9M	104.9M
Non Currrent Assets Other	1.7M	1.2M	2.3M	6.8M	828K	786.6K
Cash And Short Term Investments	271.7M	152.3M	86.7M	138.4M	170.0M	206.8M
Net Receivables	56.5M	395K	14K	28K	1.0M	959.5K
Common Stock Shares Outstanding	116.7M	110.8M	145.7M	165.7M	221.1M	232.2M
Short Term Investments	235.5M	26.0M	22.7M	92.0M	147.6M	137.0M
Liabilities And Stockholders Equity	(1.0B)	203.8M	(1.5B)	(1.5B)	229.4M	240.9M
Non Current Liabilities Total	235.3M	611K	1.2M	54.0M	104.8M	100.6M
Other Current Assets	5.3M	5.0M	2.2M	2.5M	5.1M	6.8M
Other Stockholder Equity	(190K)	1.6B	(140K)	239K	1.9B	2.0B
Total Liab	300.6M	47.4M	23.3M	77.2M	136.3M	149.0M
Property Plant And Equipment Gross	14.0M	295K	6.0M	12.9M	12.0M	11.4M
Total Current Assets	337.8M	157.7M	88.9M	140.9M	176.5M	221.8M
Accumulated Other Comprehensive Income	84K	(6K)	(10K)	(428K)	31K	32.6K
Short Term Debt	11.0M	12.2M	1.1M	1.3M	1.2M	1.1M
Other Assets	285K	(45K)	1.2M	136.9M	157.4M	165.3M
Long Term Debt	231.6M	243.9M	234.2M	48.6M	99.5M	77.2M
Property Plant Equipment	14.0M	295K	1.2M	2.1M	1.9M	1.8M
Other Liab	29.9M	55.4M	35.8M	23.3M	26.8M	43.1M
Treasury Stock	(3.8M)	(4.8M)	(7.5M)	(2.1M)	(1.9M)	(1.9M)
Net Tangible Assets	52.8M	111.8M	69.1M	72.6M	65.3M	67.6M
Retained Earnings Total Equity	(1.3B)	(1.4B)	(1.5B)	(1.6B)	(1.4B)	(1.5B)
Capital Surpluse	1.5B	1.6B	1.6B	1.7B	2.0B	1.5B
Inventory	1.9M	4.7M	4.2M	1.0	381K	362.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Lexicon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexicon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexicon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexicon Pharmaceuticals Stock:

How To Invest In Lexicon

Details

Is Lexicon Stock a good investment?

Details

What is Lexicon Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Lexicon Stock analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	CEOs Directory Screen CEOs from public companies around the world

Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.63)

Earnings Share

(0.83)

Revenue Per Share

0.01

Quarterly Revenue Growth

46.083

Return On Assets

(0.40)

The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lexicon Net Receivables vs Cash And Short Term Investments Analysis

Net Receivables vs Cash And Short Term Investments

Net Receivables vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Net Receivables

Cash And Short Term Investments

Lexicon Pharmaceuticals fundamental ratios Correlations

Lexicon Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lexicon Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Lexicon Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Total Liab	+ 0.95	Non Current Liabilities Total
Total Current Assets	+ 0.9	Short Term Investments

Common Stock Shares Outstanding	- 0.89	Retained Earnings
Cash	- 0.86	Net Debt
Common Stock	- 0.75	Retained Earnings
Other Assets	- 0.6	Retained Earnings
Cash And Short Term Investments	- 0.6	Net Debt
Net Debt	- 0.57	Total Assets